Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
China Pharma Holdings, Inc. will seek approval on December 22, 2026 for a reverse stock split at a ratio of up to 1:50, election of three independent directors, and Amendment No.4 to its 2010 Long-Term Incentive Plan.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Anti-Viral/ Infection & Respiratory revenue mix percentage | 33% | three months ended June 30, 2026 filing | — |
| CNS Cerebral & Cardio Vascular revenue mix percentage | 53% | three months ended June 30, 2026 filing | — |
| Cost of revenue as a percentage of total revenue | 91.2% | three months ended June 30, 2026 filing | — |
| Digestive Diseases revenue mix percentage | 13% | three months ended June 30, 2026 filing | — |
| General and administrative expenses as a percentage of total revenue | 145.2% | three months ended June 30, 2026 filing | — |
| Gross profit margin | 8.8% | three months ended June 30, 2026 filing | — |
| Other revenue mix percentage | 1% | three months ended June 30, 2026 filing | — |
| Research and development expenses as a percentage of total revenue | 2% | three months ended June 30, 2026 filing | — |
| Selling expenses as a percentage of total revenue | 12% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CPHI
this stock
China Pharma Holdings, Inc.
|
$22.80M | -52.9% | -8.5% | — | 0.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.16B | +34.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$55.28B | +12.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.72B | +36.5% | +4.3% | 96.8 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
China Pharma Holdings, Inc. will seek approval on December 22, 2026 for a reverse stock split at a ratio of up to 1:50, election of three independent directors, and Amendment No.4 to its 2010 Long-Term Incentive Plan.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CPHI | -8.8% | -34.5% | -23.0% | -8.8% | -52.9% |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -6.1% | -29.0% | -22.5% | -6.1% | -60.7% |
